New biologic IBI311 shows promise for thyroid eye disease in early trial
NCT ID NCT06525506
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II study tested a new biologic drug called IBI311 in 38 people with thyroid eye disease, a condition that causes eye bulging and discomfort. Participants received different doses of the drug to see if it could safely reduce eye protrusion. The trial is completed, and results will help determine if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI311 (a biologic drug given by infusion)
What this could lead to
If successful, this could lead to a new treatment option for thyroid eye disease that reduces eye bulging and improves comfort.
What could go wrong
This is an early Phase II trial with only 38 participants, so results may not apply to everyone. The drug may cause side effects or not work better than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Innovent Biologics (Suzhou) Co. Ltd
Suzhou, Suzhou, 215123, China